Gilpin Facial Plastics + Aesthetics Introduces Deep Plane Facelift Technique
New Approach to Facial Rejuvenation Gains Recognition for Its Structural Focus
Nashville, Tennessee--(Newsfile Corp. - February 7, 2025) - Gilpin Facial Plastics + Aesthetics is introducing the Deep Plane Facelift technique as part of its surgical offerings. Led by Dr. David Gilpin, the practice is implementing this approach, which has been recognized in the field of facial plastic surgery for its method of addressing deeper structural layers of the face.
Unlike traditional facelift techniques that primarily lift the skin and superficial tissues, the Deep Plane Facelift involves repositioning underlying facial structures, including the muscle layers, to enhance facial rejuvenation. Some experts in the field have discussed this approach as an alternative to conventional facelift techniques, as it aims to refine facial contours in a way that aligns with each patient's natural anatomy.
Many patients are able to resume social activities within 10 to 14 days - a notable improvement over the three to four weeks of downtime often required with traditional facelifts.
Dr. Gilpin and his team at Gilpin Facial Plastics + Aesthetics develop surgical plans tailored to each patient's unique goals. The practice specializes in a range of procedures, including rhinoplasty, eyelid surgery, neck lifts, and non-surgical aesthetic treatments, providing a comprehensive approach to facial rejuvenation.
About Gilpin Facial Plastics + Aesthetics: Gilpin Facial Plastics + Aesthetics, located in Nashville, TN, is a premier facial plastic surgery practice led by Dr. David Gilpin. A native of Nashville, Dr. Gilpin completed his medical degree at the University of Tennessee College of Medicine and received specialized training in facial plastic surgery at Tulane University. He is dual board-certified by the American Board of Facial Plastic and Reconstructive Surgery and the American Board of Otolaryngology.
For those interested in learning more about enhanced recovery with the Deep Plane Facelift or other facial rejuvenation procedures, Gilpin Facial Plastics + Aesthetics invites to visit their website.
Media Contact:
Company Name: Gilpin Facial Plastics
Contact Person: Dr. David Gilpin
Phone: (615) 942-7301
Address: 2301 21st Ave S Suite 300
City: Nashville
State: TN
Postal Code: 37212
Country: US
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Envoy Medical's Pivotal Clinical Trial for Fully Implanted Acclaim(R) Cochlear Implant Remains On Track After First Month Follow-Up
Positive momentum from the trial's first stage encouraging Company to accelerate plans for expansion and commercialization White Bear Lake, Minnesota--(Newsfile Corp. - June 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that all 10 of the study participants in the first stage of the Company's pivotal clinical trial for the fully implanted Acclaim® Cochlear Implant have successfully completed their one-month follow-up visits. The investigational sites have reported that the visits are proceeding as expected. Due to the device's breakthrough design, participants are hearing without the need for externally worn devices and have the ability to hear 24 hours a day. No serious adverse events or unanticipated device events have been reported through the first month for all 10 participants. Brent Lucas, CEO of Envoy Medical, commented, "The feedback from investigational sites after the one month follow up visits continues to be positive and indicates we are on track with our pivotal clinical trial. We continue to build positive momentum with each milestone and have begun to accelerate our thinking about expansion and preparing for commercialization. We strongly believe that, if approved, our fully implanted Acclaim® cochlear implant will enjoy substantial patient interest; allowing us a rare opportunity to grow into a significant market participant relatively quickly. We believe our investigational fully implanted Acclaim® cochlear implant is well-positioned to be able to capture market share as the industry moves towards fully implanted cochlear implants and away from bulky externals." Envoy Medical remains committed to effective and timely communication with investors. We will continue to update the shareholder community throughout the trial. For more information on the trial, please go to or To be added to the Envoy Medical email distribution list, please email Envoy@ with COCH in the subject line. About Envoy Medical, Inc. Envoy Medical (Nasdaq: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life. About the Fully Implanted Acclaim® Cochlear Implant We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The device is powered by a rechargeable battery and has an external charger to charge the internal device when necessary. In addition, patients are given an external remote or programmer to adjust settings or turn the device on or off. The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician. The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. For more information on the trial, investors can visit or CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use. About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI) The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing. Patients are given an external remote or "personal programmer" to adjust volume, switch between hearing profiles, or turn the device on or off. Important safety information for the Esteem FI-AMEI can be found at: Additional Information and Where to Find It Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the timing and results of IRB approvals, site documents, logistics or activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions or healthcare professionals in such trials; the Acclaim CI being the first to market fully implanted cochlear implant; the safety, performance, and market acceptance of the Acclaim CI; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical. ### Investor Contact:Phil CarlsonKCSA Strategic CommunicationsO: 212.896.1233E: pcarlson@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 hours ago
- Yahoo
Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies
Boston, Massachusetts--(Newsfile Corp. - June 10, 2025) - Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of Elisabeth Gardiner, Ph.D., as Chief Scientific Officer. With more than 25 years of leadership in drug discovery and development across the biotech and pharmaceutical sectors, Dr. Gardiner brings deep translational expertise that will accelerate Tevard's mission to develop effective and durable tRNA-based therapies targeting the root cause of disease. As CSO, she will lead scientific strategy and R&D operations to expand Tevard's novel platform of engineered suppressor tRNAs, which recently demonstrated the first sustained restoration of full-length dystrophin in a Duchenne Muscular Dystrophy (DMD) model. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Dr. Gardiner's experience scaling discovery and translational programs will be critical as Tevard advances their lead program toward the clinic and expands their pipeline across additional indications. Tevard Biosciences is working to unlock the potential of tRNA-based therapies. The company's programs are based on its novel Suppressor tRNA technology platform that uses a viral vector to insert the normal amino acid at the site of the premature stop codon. Tevard's lead program targeting TTN-related dilated cardiomyopathy is advancing rapidly, with new data expected in the near future. Click image above to view full announcement. About Tevard Biosciences Tevard Biosciences is pioneering tRNA-based and other mRNA-modulating therapies to cure a broad range of genetic diseases. The privately held biotechnology company was founded by renowned scientists along with life science executives and entrepreneurs who are also fathers of children with rare diseases. Tevard is advancing the use of its novel suppressor tRNA platform in heart disease, muscular dystrophies, and neurological disorders. For more information, please visit Contacts: Michelle Linn michelle@ Source: Tevard To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 hours ago
- Yahoo
CORRECTION FROM SOURCE: Bighorn Web Solutions Signs Magento Partnership with PSP Pharma to Drive E-Commerce Expansion
This release corrects and replaces the press release issued by Bighorn Web Solutions on May 29, 2025 7:30 AM EDT. The updated version has been revised to reflect accurate information and ensure consistency across all referenced materials. Denver, Colorado--(Newsfile Corp. - June 10, 2025) - Bighorn Web Solutions, a leading enterprise-grade eCommerce agency, has signed a Magento eCommerce contract with PSP Pharma. Bighorn Web Solutions is responsible for the technical development of PSP Pharma's e-commerce systems, including and the PSP mobile application. The partnership is focused on improving platform performance, user experience, and operational efficiency to better serve PSP Pharma's growing customer base. CEO of Bighorn Web Solutions, Caleb Bradley, and Mamuka Bregvadze, administrative director of PSP Pharmacy To view an enhanced version of this graphic, please visit: PSP Pharma plans to expand its e-commerce platform across the region, with a focus on increasing access to health and self-care products in the Caucasus and Central Asia. This strategic move will enable the company to strengthen its presence and drive product sales throughout these markets. PSP has its eyes set on technology innovation and global growth. They're the first pharmaceutical company in Eastern Europe to fully implement Microsoft Dynamics 365 Business Central and LS Retail, setting a new benchmark for service quality, operational efficiency, and business process integration. The agreement with Bighorn Web Solutions positions PSP to lead the region in e-commerce excellence. "Partnering with PSP Pharma aligns strongly with Bighorn's global expertise and our commitment to empowering visionary companies. Signing this contract reinforces the mutual value we are creating and reflects our role as a trusted technology partner. As PSP expands into new regional markets, we are excited to deliver the solutions that support their growth and to play a key role in shaping the future of eCommerce in the pharmaceutical sector," said Caleb Bradley, CEO of Bighorn Web Solutions. To learn more about Bighorn Web Solutions and its enterprise eCommerce development services, please visit About Bighorn Web Solutions: Bighorn Web Solutions is a U.S.-based enterprise-grade e-commerce agency rooted in the Rocky Mountain region, comprised of senior-level engineers who are specialists, not generalists. With deep expertise in its respective niches, the agency understands the importance of staying ahead in an ever-evolving digital landscape. Media Contact: Caleb BradleyCEO, Bighorn Web To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
